Alzheimer’s jab failed to meet goal on reducing memory decline, company says A new jab for people with early-stage Alzheimer’s has failed to show it can slow down a decline in memory and thinking, according to pharmaceutical giant Roche.
The drug, gantenerumab, is an antibody medicine that held much promise as it entered phase three clinical trials. The Independent
No comments:
Post a Comment